Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month

Article

In observance of Bleeding Disorders Awareness Month, held annually in March, catch up on some of the latest expert insights in gene therapies for hemophilia, which is among the most common of these disorders.

In recent months, CGTLive has interviewed multiple experts about the various gene therapies currently in development for the treatment of hemophilia A and hemophilia B, which are among the most commonly occurring bleeding disorders.

For Bleeding Disorders Awareness Month, observed annually in the month of March by the patient and clinician communities, the CGTLive team has gathered some of our latest interviews on hemophilia gene therapies below to offer expert insight on the therapeutic progress being made for these rare disorders.

Those featured include:

  • Adam Cuker, MD, associate professor of medicine at the University of Pennsylvania
  • Steven Pipe, MD, professor of pediatric hematology/oncology at CS Mott Children’s Hospital
  • Brent Warner, president of gene therapy at Poseida Therapeutics
  • Rigoberto Garcia, MPH, executive director of the Hemophilia Foundation Southern California

Click the respective slides below to watch each expert interview.


—————————————————

Recent Videos
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.